REG - Hutchmed China Ltd - 2023 Annual Report and Notice of AGM

HUTCHMED (China)Announcement

08/04/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH5501Ja&default-theme=true

RNS Number : 5501J  Hutchmed (China) Limited  08 April 2024

 

 

2023 Annual Report and Notice of Annual General Meeting

 

Hong Kong, Shanghai, & Florham Park, NJ - Monday, April 8, 2024: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM: HCM;
HKEX: 13) today announces that its 2023 Annual Report, together with the
Notice of Annual General Meeting and the Form of Proxy ("AGM Materials"), will
be posted on April 9, 2024 to those shareholders who have elected to receive
the AGM Materials in printed form. The documents can also be accessed from the
HUTCHMED website (www.hutch-med.com (https://www.hutch-med.com/) ).

 

The 2024 Annual General Meeting ("AGM") will be an electronic/hybrid meeting
to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom,
Kowloon, Hong Kong on Friday, May 10, 2024 at 5:00 pm Hong Kong Time (10:00 am
London Time), with online access through an online platform as detailed in the
AGM Materials.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three medicines marketed in China, the first of which is also
marketed in the U.S. For more information, please visit: www.hutch-med.com
(http://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS

 

 Investor Enquiries                                +852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com
                                                   (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting            +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                   +44 7779 545 055 (Mobile)   HUTCHMED@fticonsulting.com
                                                   (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                   (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang,  +44 (20) 7886 2500

Panmure Gordon

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFIVSAIEIIS